Risk Adjustment, Reinsurance Transfer Offer Financial Benefit

This article originally appeared here.
Share this content:
Risk Adjustment, Reinsurance Transfer Offer Financial Benefit
Risk Adjustment, Reinsurance Transfer Offer Financial Benefit

THURSDAY, April 6, 2017 (HealthDay News) -- Risk adjustment and reinsurance transfer programs seem to have been effective for increasing revenues at the expense of claims costs, according to research published in the March issue of Health Affairs.

Paul D. Jacobs, Ph.D., from the Agency for Healthcare Research and Quality in Rockville, Md., and colleagues examined the impact of the risk adjustment program established to equalize health-related cost differences across plans and the temporary reinsurance program to subsidize high-cost claims, both established by the Affordable Care Act (ACA). The authors compared revenues to claims costs for insurers in the individual market during the first two years of ACA implementation, before and after the inclusion of these programs.

The researchers found that claims exceeded premium revenues for the 30 percent of insurers with the highest claims costs by $90 to $397 per enrollee per month before these payments were included. After these payments were included, the effect was reversed, with revenues exceeding claims by $0 to $49 per month. In the first two years the risk adjustment and reinsurance programs were relatively well targeted.

"While there is ongoing discussion regarding the future of the ACA, our findings can shed light on how risk-sharing programs can address risk selection among insurers -- a pervasive issue in all health insurance markets," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »